Our proprietary immune profiling technology provides unparalleled insight.
A novel approach anchored in a deep understanding of patient anti-tumor immune responses
Atreca is applying its Immune Repertoire Capture™ technology to generate and develop a novel class of cancer immunotherapies including therapeutics that optimize anti-tumor immune responses in synergy with checkpoint inhibitors and immune activators.
Atreca is continuing to build a product portfolio designed to meet evolving patient needs in cancer treatment. Based upon the ability to identify the antibodies and targets that drive a productive anti-tumor immune response, the Company’s discovery platform enables multiple classes of agents, as noted below.
In addition, as a result of our research and development collaborations with a variety of partners, we have several advancing programs in non-oncology areas.